Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (121-130 of 367) with videos related to

Pageof 37
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2020
A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint InhibitorsMirte Muller, Karlijn Hummelink, Daan P Hurkmans, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 29, 2010
The finding of premalignant lesions is not associated with smoking cessation in chemoprevention study volunteersRomane M Schook, Berber B M Postmus, Remco M van den Berg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 10, 2002
Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PETCorneline J Hoekstra, Otto S Hoekstra, Sigrid G Stroobants, et al.
Current Medical Research and Opinion|June 16, 2012
Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational studyAlain Vergnenegre, Egbert F Smit, Elisabeth Toy, et al.
EJNMMI Research|February 10, 2016
Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLCIdris Bahce, Maqsood Yaqub, Hanane Errami, et al.
Lung Cancer (Amsterdam, Netherlands)|February 10, 2015
Second primary lung cancers following a diagnosis of primary head and neck cancerGwendolyn H M J Griffioen, Alexander V Louie, Remco de Bree, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2022
Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trialArd van Veelen, Judith Gulikers, Lizza E L Hendriks, et al.
Current Medical Research and Opinion|October 15, 2010
Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational studyDenis Moro-Sibilot, Alain Vergnenegre, Egbert F Smit, et al.
Drugs|December 11, 2021
Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung CancerRené J Boosman, Jacobus A Burgers, Egbert F Smit, et al.
The Journal of Molecular Diagnostics : JMD|March 20, 2012
KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNADaniëlle A M Heideman, Irene Lurkin, Marije Doeleman, et al.
Pageof 37

Showing results (121-130 of 367) with videos related to

Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2020
A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint InhibitorsMirte Muller, Karlijn Hummelink, Daan P Hurkmans, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 29, 2010
The finding of premalignant lesions is not associated with smoking cessation in chemoprevention study volunteersRomane M Schook, Berber B M Postmus, Remco M van den Berg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 10, 2002
Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PETCorneline J Hoekstra, Otto S Hoekstra, Sigrid G Stroobants, et al.
Current Medical Research and Opinion|June 16, 2012
Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational studyAlain Vergnenegre, Egbert F Smit, Elisabeth Toy, et al.
EJNMMI Research|February 10, 2016
Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLCIdris Bahce, Maqsood Yaqub, Hanane Errami, et al.
Lung Cancer (Amsterdam, Netherlands)|February 10, 2015
Second primary lung cancers following a diagnosis of primary head and neck cancerGwendolyn H M J Griffioen, Alexander V Louie, Remco de Bree, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2022
Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trialArd van Veelen, Judith Gulikers, Lizza E L Hendriks, et al.
Current Medical Research and Opinion|October 15, 2010
Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational studyDenis Moro-Sibilot, Alain Vergnenegre, Egbert F Smit, et al.
Drugs|December 11, 2021
Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung CancerRené J Boosman, Jacobus A Burgers, Egbert F Smit, et al.
The Journal of Molecular Diagnostics : JMD|March 20, 2012
KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNADaniëlle A M Heideman, Irene Lurkin, Marije Doeleman, et al.
Pageof 37